<p>Ipsen SA reported its full year (FY) 2025 financial results, posting total sales of EUR 3,675.9 million, an increase of 8.1% compared to the previous year. Core operating income for FY 2025 stood at EUR 1,294.1 million, reflecting a significant rise of 16.7%. For 2026, Ipsen SA provided financial guidance, targeting total sales growth of more than 13.0% and a core operating margin above 35.0% of total sales. The company expects accelerated growth from its portfolio excluding Somatuline, as well as continued growth in Somatuline sales due to generic lanreotide production challenges. The guidance also anticipates increased R&amp;D expenses from early and mid-stage external innovation opportunities. Ipsen SA highlighted expectations for five major regulatory and clinical milestones in 2026, alongside a full data readout for IPN10200 in an aesthetics indication. The company plans to release its first quarter 2026 sales on April 23, 2026. Comprehensive audited financial statements will be made available on its website in due course. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164329-en) on February 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

159898

159837

LABU

Reuters

Ipsen SA FY 2025 core operating income rises 16.7% to EUR 1.29 billion